Purpose:
Exploration of phospholipid balance, genetic expression, impact of toxicity and longevity through examination of fatty acid imbalances revealed through red cell lipid biopsy from Johns Hopkins with definitive medical approaches towards metabolic stability of lipid metabolism and longevity.
Objectives:
1. OVERVIEW OF A NEW TECHNOLOGY TO ASSESS CELL MEMBRANE
FUNCTION AND FATTY ACID CONTENT IN REGARD TO PHOSPHOLIPID BALANCE / SUFFICIENCY, TOXICITY STATUS AND LONGEVITY
2. DISCUSS THE CLINICAL FEATURES OF CONTROL OF LIPID, PHOSPHOLIPASE A2 (PLA2) AND PROSTAGLANDIN METABOLISM THROUGH FATTY ACID AND COFACTOR MANIPULATION
3. APPRECIATE THE PROFOUND INFLUENCE TARGETED FATTY ACID
THERAPY HAS UPON CELLULAR FUNCTION AND MICROTUBLE
STRUCTURE IN REGARD TO LONGEVITY
Conclusion:
Characteristic findings in aging as the accumulation of very long chain fatty acids (VLCFAs) in states of toxicity, omega 3 and omega 6 imbalance/ deficiency, disturbed prostaglandin synthesis, overexpression of PLA2, poor cellular integrity and aberrant lipid production may be managed by opening a gateway into cellular metabolism with metabolic intervention (cofactors, substrates) through manipulation of cell membrane lipids and thereby impacting the systemic nature of the aging process.
Assessing the stability of the cell membrane through the examination of red cell lipids leads the clinician into a wide realm of metabolic strategies to influence the health of patient longevity. Lipids evolve into hormones, the bilipid layer of every cell in the body, prostaglandins, immune components, and myelin…. There is virtually no system of the body that does not require attenuation of specific fatty acid substrates and coenzymes to maintain health and repair of bodily tissues. The human cell membrane cannot be created nor its function controlled without respect to lipid substrate, yet fatty acid metabolism has been poorly delineated and often simply ignored in treatment protocols. Exploration of lipid metabolism brings a striking new tool that unlocks some of the complexities of longevity as lipid imbalance and deficiency have an intimate link to the endocrine, hepatic, renal, CNS, gastrointestinal, pulmonary, musculoskeletal and cardiovascular systems as well as exquisite capacity to impact aging.
The membrane of every cell and organelle is a lipid envelope that encases and protects the internal working cellular components. The bilipid layer is far more than isolation and protection, for linked and interlocked within the membrane are literally thousands of proteins (peptides) large and small that form the windows and doors of the cell. These mucopolypeptides form the gates for ingress and egress but also provide the multitudinous array of receptors that trigger not only access but create the vast intercellular communication and information system through their prostaglandin regulatory activity. Prostaglandins may have evolved to be the basic control mechanism that permitted metazoa agglomeration (which is principally what we are, a vast agglomeration of cells) since emerging from the primordial sea millions of years ago. Thus the mere thought of multicellular activity, and especially the evolution of humankind is, at our present level of knowledge, not possible without essential fatty acids, which are the precursors to the regulatory prostaglandins, which provide the communication and control absolutely necessary for a group of cells to stay together. Before one can advance beyond unizoa or single cell organisms into multi-cell metazoa there must be both communication and eventually a means of regulation. This is the marvelous, magical world of the prostaglandins (PGs), the “local hormones” that control all cell to cell interactions without which there is no complex life form.
The explosion of fatty acid studies appearing in medical research have led us into a new era in our approach to resolving disease and the aging process, however, the focus of medical lipid manipulation has led to a great deal of confusion as pharmaceutical companies often dictate individual fatty acids as drugs rather than essential nutrients. As we begin to unfold the incredible complexity of lipid metabolism in the body human we are forced to acknowledge that lipid individuality must be respected if we are to achieve positive patient outcomes as we approach the process of longevity.
Lipids vibrate in the cell at millions of times/second. The double bonds of the omega 6 and omega 3 lipids are the singing backbone of life expressed through their high energy level. These bonds are their vibratory song, and they absolutely carry a tune befitting every act and function in the exercise of life, providing all 70 trillion of our cells their flexible nature. When renegade fats are over represented in the cell membrane they result in off key expression, and if strong enough, may spell cellular death and apoptosis. Healing the outer leaflet of the membrane, comprised primarily of phosphatidylcholine, with phospholipid therapy, is our highest priority in addressing chronic illness and aging.
The cellular impact of aging and toxic burden results in disturbed prostaglandin synthesis, poor cellular integrity, decreased GSH levels, significant suppression of omega 6 arachidonic acid, imbalance of EFAs, marked elevation of Renegade fats and ultimately with demyelination (depressed DMAs). The presence of VLCFAs (very long chain fatty acids) are evidence of peroxisomal dysfunction and suppression of the beta oxidation of lipids and cellular respiration. Renegade fats (VLCFAs, Odd Chains, Branched Chains) are represented as an increase in fat content in the brain as discovered in stroke patients examined by Stanley Rapoport, Chief of the Laboratory of Neuroscience at the NIH. Biotoxins and heavy metals are lipid soluble thus the effect upon cellular processes and hepatobiliary function is often gravely deranged. Often in the aging process patients do not possess a gross burden of toxins but rather a burden that has a finite impact upon the cell by blocking receptor sites such as G proteins, which act as a relay system through the cell.
Renegade fats such as very long chain fatty acids (VLCFA) that are over expressed, disrupt the membrane structure. There is a beautiful geometry to the membrane that is highly sensitive to the size of the lipid chains. The overall width of the fatty acid portion of the membrane is ~3 ½ nm which must be maintained for stability. Saturated or monounsaturated fatty acids with a length of 16 or 18 carbons are preferred to permit the structure to maintain optimal horizontal fluidity. VLCSFAs that range from 20 to 26 carbons force the parallel dimensions vertically. There simply is not enough room. The distortion weakens the phosphate bonds that derive their strong attraction only as long as the phospholipids are parallel to each other on both sides of the membrane. The cell weakness is then expressed in leaky attraction to ion channels and receptors which marginalize cell cytosol fluids and electrolytes with the only option as early cell death.
In states of aging it is paramount to stabilize omega 6 fatty acids and the lead eicosanoid Arachidonic acid before introducing omega 3 lipids. The manipulation of lipid distortion involves two basic essential fats: omega 6 and omega 3. There exists a crucial balance between omega 6 and omega 3 fatty acids in human lipid metabolism which has only recently been brought into clearer focus through the work of Yehuda (1998). His development of the SR-3 (specific ratio of omega 6 to omega 3) has revealed that the optimum ratio of omega 6 to omega 3 FAs is 4:1. AA, the lead eicosanoid, must be stable first along with the other w6 EFAs before w3 fatty acids are introduced and balanced. Clinicians are often met with poor patient outcomes when merely administering omega 3 lipids without first introducing omega 6 fatty acids, stabilizing the structural lipids, increasing the fat content of the diet, stimulating the ß-oxidation of renegade fatty acids, flushing of the gall bladder/biliary tree and supporting digestion of fats with bile salts and lipase.
The body loses its ability to metabolize fats in states of toxicity and therefore becomes depleted in the eicosanoids and prostaglandins. Essential fatty acids are the precursors to the regulatory prostaglandins which are “local hormones” providing the communication controlling all cell to cell interactions. The human cell membrane cannot be supported nor its function controlled without respect to lipid substrate, yet fatty acid metabolism has been poorly delineated in the medical literature. An optimum balance of fatty acids make up the dynamic membrane. The membrane of every living cell and organelle is composed of two fatty acid tails facing each other. This bilipid layer is so minute (3 nanometers) that it would take 10,000 membranes layered on top of each other to make up the thickness of this paper. Yet the dynamics that occur within this tiny envelope with organelles prancing up and down the cytoskeleton microtubules is a microcosm that is a challenge for the human mind to envision. All cells must synthesize molecules and expel waste. All cells must create, through gene expression, the proteins needed for cellular gates embedded in the membrane as ion channels and receptors. The ultimate control of how those peptides behave rests with the character of the membrane while the integrity of the membrane rests with the structural (oleic, stearic, palmitic, cholesterol) and essential lipids (omega 6, omega 3). Without control of membrane function through lipid manipulation, the process of longevity and detoxication is compromised. In essence, the life of the cell is intimately tied to membrane health and the health of the entire organism.
Our clinical protocol for longevity at the WellSpring Clinic in Wayne, PA is to initiate treatment with changing the patients’ overall diet, addressing the lipid balance and especially the outer lipid leaflet of the cell membrane through fatty acid therapy and the addition of supplementation targeted towards dissolving fibrin, clearing the liver/biliary tree, and healing the cell membrane.
Blood thinning agents such as Heparin and Warfarin increase blood flow around the blocked endothelium, however, reconstituting membrane fluidity can directly address coagulation in a natural restorative way. Vibrant healthy membranes will not permit agglomeration. The high polyunsaturated lipids with a preponderance of phosphatidylcholine on the plasmic surface precludes undesirable clumping to occur. Treatment modalities should address dissolving fibrin and healing the cell membrane. By stabilizing lipid status with intravenous Phospholipid exchange and oral EFA supplementation we have remarkable tools to unload the body burden of neurotoxins in both pediatric and adult populations, without side effects. Oral use of phospholipids is also an effective intervention in addressing the aging process.
Through isolating individual fatty acids and dimethyl acetyls in red cells we can now examine the cellular integrity/structure, fluidity, the formation of renegade fats that impair membrane function, myelination status, and the intricate circuitry of the prostaglandins. The systemic health of the individual patient may be reached and targeted nourishment utilized through evidence based intervention which may yield positive patient outcome. Healing the membrane is virtually…. Healing the brain.
Phospholipids, cholesterol, cerebrosides, gangliosides and sulfatides are the lipids most predominant in the brain residing within the architectural bilayers. The phospholipids and their essential fatty acid components provide second messengers and signal mediators. In essence, phospholipids and their essential fatty acid components play a vital role in the cell signaling systems in the neuron. The functional behavior of neuronal membranes largely depends upon the ways in which individual phospholipids are aligned, interspersed with cholesterol, and associated with proteins. All neurotransmitters are wrapped up in phospholipid vesicles. The release and uptake of the neurotransmitters depends upon the realignment of the phospholipid molecules. The nature of the phospholipid is a factor in determining how much neurotransmitter or metal ion will pass out of a vesicle or be taken back in. Phospholipid re-modeling may be accomplished by supplying generous amounts of balanced lipids and catalysts via nutritional intervention and the use of intravenous Phospholipid Exchange.
Newly documented research delineates how targeted lipid manipulation can dramatically influence the body human. Medicine has been slow to recognize lipid requirements to address neurological degeneration often accompanying states of aging. Data is now emerging from the medical literature but it must organized into meaningful therapeutic applications for use in a clinical setting. By organizing the research data and isolating individual fatty acids in red cells we can now examine the cellular integrity/structure, fluidity, the formation of renegade fats that impair membrane function, myelination status, PLA2 status and the intricate circuitry of the prostaglandins and for the first time lipid treatment protocols may be established due to a clearer view into red cell membrane dynamics.
Examination of red cell lipids in patients age 50 with endocrine imbalance, immune dysfunction, hepatic involvement, Alzheimers, Post Stroke, Cardiovascular disease, ALS, cognitive impairment, Parkinson’s Disease, Glaucoma, Cataracts, gastrointestinal difficulties, hypercoagulation, CFS, MS, Depression, states of toxicity, CNS degeneration… reveal characteristic patterns that may be addressed with targeted lipid manipulation, stabilization of the membrane traffic through electrolytes, catalysts, medical foods, and metabolic nutritional therapy. Medical data gleaned from the in depth analysis of red cell lipid biopsy via 10,000 analyses in our database is directly applicable to longevity protocols.
References
Aoyama T, Souri M, Kamijo T, Ushikubo S, Hashimoto T Peroxisomal Acyl-Coenzyme A
Oxidase is a Rate-Limiting Enzyme in a Very-Long-Chain Faty Acid ß-Oxidation
System Biochemical and Biophysical Res Com 201:3:1541-1547 June 30, 1994
Araki E, Kobayashi T, Kohtake N, Goto I, Hashimoto A Riboflavin-Responsive Lipid Storage
Myopathy Due to Multiple AcylCoA Dehydrogenase Deficiency: An Adult Case
J of the Neurological Sciences 126:202-205, 1994
Ara G, Teicher BA Cyclooxygenase and Lipoxygenase Inhibitors in Cancer Therapy
Prostaglandins Leukotrienes and Essential Fatty Acids 54:3-16, 1996
Aschner M, Aschner JL Mercury Neurotoxicity: Mechanisms of Blood-Brain
Barrier Transport Neurosci Biobehav Rev 14:169-176, 1990
Aschner M et al Induction of Astrocyte Metallothioneins by Zn confers resistance
against the acute cytotoxic effects of Methylmercury on cell swelling, Na
uptake and K release Brain Research 813:254-261, 1998
Attwell D, Miller B, Saantis M Arachidonic Acid as a Messenger in the Central Nervous System
Seminars in the Neurosciences 5: 159-169, 1993
Bazan NG, Murphy MG, Toffano G Neurobiology of Essential Fatty Acids Advances in
Experimental Medicine and Biology Vol 318 from the proceedings July 10-12,1991
in Palm Cove, Far North Queensland, Australia, Plenum Publishing, NYC,1992
Baumgart E, Volkl A, Pill J, Fahimi HD Profileration of Peroxisomes without Simultaneous
Induction of the Peroxisomal Fatty Acid ß-oxidation Federation of European
Biochemical Societies Letters 264:5-9,1990
Behan PO, Behan WMH, Horrobin DF Effec of High Doses of Essential Fatty Acids on the Postviral
Fatigue Syndrome Acta Neurol Scand 82:209-216, 1990
Beier K, Volkl A Fahimi HD Suppression of Peroxisomal Lipid ß-oxidation enzymes by
TNF-alpha FEBS Lett 310:273-278,1992
Bentley P, Calder I, Elcombe C, Grasso P, Stringer D, Wiegand HS Hepatic Peroxisome
Proliferation in rodents and its significance for Humans Food Chem Toxic
31:857-907,1993
Blok WL, Katan MB, Meer JWM Modulation of Inflammation and Cytokine Production by
Dietary (n-3) Fatty Acids J Nutr 126:1515-1533, 1996
Boulanger C, Schini VB, Hendrickson H, Vanhoutte PM Chronic Exposure of Cultured Cells
to Eicosapentaenoic acid potentiates the Release of Endothelium-derived Relaxing
Factor(s) British J Pharmacology 99:176-180, 1990
Brown FR, Voight R, Singh AK, Singh I Peroxisomal Disorders AJDC 147, June 1993
Caruso L, Trischitta C, Bertino G, Amore MG, Rapisarda F, Calcara G Polyunsaturated
Pholsphatidylcholine in the treatment of Hepatic Steatosis
Clin Ter 107:4:279-290, Nov 30, 1983
Clandinin MT, Jumpsen J, Suh M Relationship between Fatty Acid Accretion, Membrane
Composition and Biological Functions J of Pediatrics 125:5:S25-S32 Nov 1994
Collier GR, Sinclair AJ Role of N-6 and N-3 Fatty Acids in the Dietary Treatment of Metabolic Disorders
Annals NY Acad Sci 322-329, 1993
Crawford MA A Biochemical Theory on the Evolution of the Human Brain After-Dinner
Speech at the Proceedings From the Scientific Conference on Omega-3 Fatty Acids
Nutrition, Vascular Biology, and Medicine Houston, TX April 17-19, 1994
Delion S, Chalon S, Guilloteau D, Besnard JC, Durand G Alpha Linolenic Acid Dietary Deficiency
Alters Age-Related Changes of Dopaminergic and Sertoninergic Neurotransmision in the
Rat Frontal Cortex J of Neurochem 66:1582-1591, 1996
Dias VC, Parsons HG Modulation in delta 9, delta 6, and delta 5 fatty acid desaturase
Activity in the Human Intestinal CaCo-2 Cell Line J of Lipid Research 36:552-563, 1995
Diczfalusy U ß-Oxidation of Eicosanoids Prog Lipid Res 33:4:403-428, 1994
Endres S Omega 3 Polyunsaturated Fatty Acids and Human Cytokine Synthesis Lipids 31:S239-S242, 1996
Farooqui AA et al Inhibitors of intracellular phospholipase A2 activity: Their neurochemical effects
and therapeutic importance of neurological disorders Brain Res Bull 49:3:139-153, Jun 1999
Flood JF, Morley JE, Roberts E Memory enhancing effects in male mice of Pregnenolone and
Steroids Metabolically Derived from it. Proc Natl Acad Sci USA 89:1567-1571,1992
George MS, Guidotti, Rubinow D, Pan B, Mikalauskas K, Post RM CSF Neuroactive Steroids in
Affective Disorders: Pregnenolone, Progesterone, and DBI Biol Psychiatry 35:775-780,1994
Gibson GG, Milton MN, Elcombe CR Induction of Cytochrome P450 IVA 1-Mediated Fatty Acid
Hydroxylation: Relevance to Peroxisome Proliferation Biochemical Society Transactions
18:97-99, 1990
Gibson GG, Lake B Peroxisomes: Biology and Importance in Toxicology and Medicine
Taylor and Francis: London, 1993
Gordon JA, Heller SK, Rhead WJ, Watkins PA, Spector AA Formation of a Novel Arachidonic
Acid Metabolite in Peroxisomes Prostaglandins Leukotriences and Essential Fatty
Acids 52:77-81, 1995
Guengerich FP Reactions and Significance of Cytochrome P450 Enzymes Journal of Biological
Chemistry 266:10019-10023, 1991
Hayashi H, Takahata S Role of Peroxisomal Fatty Acyl-CoA Beta-Oxidation in Phospholipid
Biosynthesis Archives of Biochemistry and Biophysics 284:326-331, 1991
Horrobin DF Fatty Acid Metabolism in Health and Disease: The Role of delta-6-Desaturase
Am J Clin Nutr 57(suppl):732S-7S, 1993
Horrobin DF Nutritional and Medical Importance of Gamma-Linolenic Acid Prog Lipid
Res 31:2:163-194, 1992
Horrobin DF DNA-Protein and Membrane-Lipid: Competing Paradigms in Biomedical Research
Med Hypotheses 44:4:229-232, Apr 1995
Horrobin DF, Glen AIM Hudson CJ Possible Relevance of Phospholipid Abnormalities and
Genetic Interactions in Psychiatric Disorders: The Relationship Between Dyslexia and
Schizophrenia Medical Hypotheses 45:605-613, 1995
Horrobin, DF Schizophrenia: The Illness that Made Us Human Medical Hypothesis 50:269-288, 1998
Issemann I, Green S Activation of a Member of the Steroid Hormone Receptor Superfamily
by Peroxisome Proliferators Nature 347:645-650,1990
Jakobs BS, Wanders RJA Conclusive Evidence that VLCFAs are Oxidized Exclusively in
Peroxisomes in Human Skin Fibroblasts Biochemical and Biophysical Research
Communications 178:842-847, 1991
Jenkins PJ, Portmann BP, Eddleston AL, Williams R Use of Polyunsaturated
Phosphatidyl Choline in HbsAg negative Chronic Active Hepatitis:
Results of a Prospective Double-blind Controlled Trial Liver 2:2:77-81, Jun 1982
Kane PC, Kane E Peroxisomal Disturbances in Autistic Spectrum Disorder J. Ortho Med 12:4:207-218, 1997
Kane PC Peroxisomal Disturbances in Children with Epilepsy, Hypoxia and Autism
Prostaglandins, Leukotrienes and Essential Fatty Acids 57:2:265, Aug 1997
Kane PC The Neurobiology of Lipids in Autistic Spectrum Disorder J Ortho Med 14:2:103-109, 1999
Kane PC Suppression of Peroxisomal Respiration in Children with Autistic Spectrum Disorder: Pattern
Recognition and Neurobiological Role of Treatment Protocol Int Conference Brain Uptake
and Utilization of Fatty Acids, Presented March 2-3, 2000
Kamp F, Zakin D, Zhang F,Noy N, Hamilton JA Fatty Acid Flip-Flop in Phospholipid
Bilayers is Extremely Fast Biochemistry 34:11928-11937, 1995
Kelly DS, Branch LB, Love JE, Taylor PC, Rivera YM, Iacono JM Dietary Gamma Linolenic acid
and Immunocompetence in Humans Am J Clin Nutr 53:40-46, 1991
Kerckaert I, Claeys A, Just W, Cornelis A, Roels F Automated image analysis of rat liver
Peroxisomes after treatment with Thyroid Hormones: Changes in number, size and
Catalase Reaction Micron Microsc Acta 20:9-18, 1989
Kim HY, Edsall L, Ma YC Specificity of Polyunsaturated Fatty Acid Release from rat
Brain Synaptosomes Lipids 31:S229-S233,1996
Kolde G, Kessler E, Van Husen N, Themann H Ultrastructural-morphometric analysis of
Polyenylphosphatidylcholine(PPC) treated cholestatic rat liver
Z Gastroenterol 16:10:625-639, Oct 1978
Kunau WH, Dommes V, Schulz H ß-Oxidation of Fatty Acids in Mitochondria, Peroxisomes and
Bacteria: A Centruy of Continued Progress Prog Lipid Res 34:4:267-342, 1995
Kremer JM Effects of Inflammatory and Immune Parameters in Patients with Rheumatic
and Inflammatory Disease Receiving Dietary Supplementation of Omega 3 and
Omega 6 Fatty Acids Lipids 31S243-S247, 1996
Lawson DL, Mehta JL, Saldeen K, Mehta P, Saldeen TG Omega-3 Polyunsaturated Fatty acids
augment Endothelium-dependent Vasorelaxation by Enhanced Release of EDRF and
Vasodilator Prostaglandins Eicosanoids 4:217-223,1991
Leiper JM, Birdsey GM, Oatey PB Peroxisomes Proliferate Trends in Cell Biol 5:435-437, Nov 1995
Luers G, Beier K, Hashimoto T, Fahimi HD, Volki A Biogenesis of Peroxisomes: Sequential
Biosynthesis of the Membrane and Matrix Proteins in the course of Hepatic Regeneration
European J of Cell Biology 52:175-184, 1990
Mannaerts GP, Van Veldhoven PP Role of Peroxisomes in Mammalian Metabolism Cell
Biochem Funct 10:141-151, 1992
Martin-Requero A, Cipres G, Rivas T, Ayuso MS, Parrilla R Reciprocal Changes in
Gluconeogenesis and Ureagenesis Induced by Fatty Acid Oxidation Metabolism
42:12:1573-1582, Dec 1993
Marzo I, Alava MA, Pineiro A, Naval J Biosynthesis of Docosahexanaenoic Acid in Human
Cells: Evidence that Two Different Delta 6-Desaturase Activities may exist
Biochimica et Biophsica Acta 1301:263-272, 1996
Mayatepek E et al Impaired Degradation of Leukotrienes in Patients with Peroxisomal
Deficiency Disorders J Clin Invest 91: 881-888, March 1993
McGiff JC Cytochrome P-450 Metabolism of Arachidonic Acid Annu Rev Pharmacol Toxicol
31:339-369, 1991
Merrill JE Interleukin 2 Effects in the Central Nervous System Ann NY Acad Sci 594:188,1990
Minghetti L, Polazzi E, Nicolini A, Creminon C, Levi G Interferon Gamma and Nitric Oxide
Down Regulate Lipopolysaccaride-Induced Prostanoid Production in Cultured Rat
Microglial Cells by Inhibiting Cyclooxygenase-2 Expression
J of Neurochem 66:1963-79,1996
Moore SA, Yoder E, Spector AA Role of the Blood-Brain Barrier in the Formation of Long-Chain
Omega-3 and omega-6 Fatty Acids from Essential Fatty Acid Precursors
J of Neurochem 55:2:391-402, 1990
Moser HW Peroxisomal Diseases Adv Pediatr 1-38, 1989
Moser AB, Jones DS, Raymond GV, Moser HW Plasma and Red Blood Cell Fatty Acids in
Peroxisomal Disorders Neurochemical Research 24:2:187-197, 1999
Naito Y, Konishi C, Ohora N Blood Coagulation and Osmolar Tolerance of
Erythrocytes in Stroke-Prone spontaneously Hypertensive rats given
rapeseed oil or soybean oil as the only dietary fat
Toxicology Letters 116:3:209-215, 2000
Poll-The BT, Roels F, Ogier H et al A New Peroxisomal Disorder with Enlarged Peroxisomes
and a Specific Deficiency of Acyl-CoA oxidase (pseudo-neonatal adrenoleukodystrophy)
Am J Hum Gen 42:422-434, 1988
Ram PA, Waxman DJ DHEA 3 ß-sulfate is an Endogenous activator of the Peroxisome-
Proliferation Pathway: Induction of Cytochrome P450 4A and Acyl-Co oxidase mRNAs
in Primary rat Hepatocyte culture and Inhibitory effects of Ca Channel Blockers
Biochem J 301:753-758, 1994
Rao MS, Musunuri S, Reddy JK DHEA-induced Peroxisomal Proliferation in the rat liver
Pathobiology 60:82-86,1992
Rao MS, Ide H, Alveres K et al Comparative effects of DHEA and related Steroids on Peroxisome
Proliferation in rat liver Life Sci 52:1709-1716,1993
Rapoport SI In Vivo Labeling of Brain Phospholipids by Long-Chain Fatty Acids: Relation to
Turnover and Function Lipids 31:S97-S101,1996
Reddy JK Peroxisomal Lipid Metabolism Annu Rev Nutr 14:343-70, 1994
Robertson RP Molecular Regulation of Prostaglandin Synthesis: Implications for Endocrine
Systems TEM 6:9/10?293-297,1995
Roels F, Espeel M, Poggi F, Mandel H, Van Maldergem L, Saudubray JM Human Liver Pathology
in Peroxisomal Diseases: A Review including Novel Data Biochimie 75:281-292,1993
Roels F, De Bie S, Schutgens RBH, Besley GTN (eds) Diagnosis of Human Peroxisomal
Disorders (entire journal) J Inherited Metabolic Disease 18, Supp 1:1-226, 1995
Roels F, Espeel M, De Craemer D Liver Pathology and Immunocytochemistry in Congenital
Peroxisomal Diseases: A Review J Inher Metab Dis 14:853-875,1991
Robertson RP Molecular Regulation of Prostaglandin Synthesis TEM 6:9/10:293-297, 1995
Rubin D, Laposata M Cellular Interactions between n-6 and n-3 Fatty Acids: A Mass Analysis
of Fatty Acid Elongation/Desaturation, Distribution Among Complex Lipids, and
Conversion to Eicosanoids J of Lipid Research 33:1431-14,1992
Rustan AC, Christiansen EN, Drevon AC Serum lipids, Hepatic Glycerolipid Metabolism
and Peroxisomal fatty acid oxidation in rats fed omega-3 and omega-6 fatty acids
Biochem J 283:333-339,1992
Saito M, Iimori Y, Kamoshita S, Yanagisawa M, Sakakihara Y Effects of Peroxisomal
ß-Oxidation Antagonist on 2,3-Cyclic-Nucleotide 3-Phosphohydrolase, Membrane Lipid
Compositions, and Membrane Fluidity in C-6 Glial Cells Biochemica et Biophysica Acta
1235:178-182, 1995
Schachter D, Abbott RE, Cogan U, Flamm M Lipid Fluidity of the individual hemileaflets
in human erythrocyte membranes Ann N Y Acad Sci 414:19-28, 1983
Sharma R, Lake BG, Foster J, Gibson GG Microsomal Cytochrome P452 Induction and Peroxisomal
Proliferation by Hypolipidaemic Agents in Rat Liver: A Mechanistic Inter-Relationship
Biochem Pharm 37:1193-1201, 1988
Siesjo BK., Katsura K Ischemic Brain Damage: Focus on Lipids and Lipid Mediators Neurobiology
of Essential Fatty Acids Edited by Bazan NG et al New York: Plenum Press 1992
Slabas AR, Brown A, Sinden BS, Swinhoe R, Simon JW, Ashton AR, Whitfeld PR, Elborough KM
Pivotal Reactions in Fatty Acid Synthesis Prog Lipid Research 33:1/2:39-46, 1994
Smeland TE, Nada M, Cuebas D, Schulz H NADPH-dependent ß-Oxidation of Unsaturated Fatty
Acids with Double bonds Extnding from Odd-Numbered Carbon Atoms Proc Natl
Acad Sci 89:6673-6677, Aug 1992
Thompson GA The Regulation of Membrane Lipid Metabolism CRC Press: Boca Raton, FL, 1992
Tiin SJ, Lin TH Effects of Metallic Antioxidants on Cadmium-catalyzed Peroxidation
of Arachidonic Acid Annals of Clin and Lab Sci 28:1:43-50, 1998
Vamecq J, Vallee L, Lechene de la Porte P el al Effect of Various n-3/n-6 Fatty Acid Ratio
contents of High Fat diets on rat liver and Heart Peroxisomal and Mitochondrial
ß-oxidation Biochim Biophys Acta 1170:151-157, 1993
Van den Bosch H, Schutgens RBH, Wanders RJA, Tager J Biochemistry of the Peroxisomes
Annu Rev Biochem 61:157-197,1992
Xu L, Ash M, Abdel-Aleem S, Lowe JE, Badr M Hyperinsulinemia Inhibits Hepatic Peroxisomal
ß-Oxidation in Rats Hormone Metabolism Research 27:76-78, 1995
Yehuda S, Rabinovitz S, Carasso RL, et al: Fatty acids and brain peptides. Peptides, 1998; 19:2:407-419.
